格隆汇2月2日丨南新制药（维权）(688189.SH)公布，截至2026年1月31日，公司通过上海证券交易所交 易系统以集中竞价交易方式累计回购公司股份1,910,214股，占公司总股本的比例为0.70%，回购成交的 最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人民币16,138,029.08元（不含印花税、交易 佣金等交易费用）。 ...

Summary of Key Points Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has announced a share buyback program, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1: Share Buyback Details - The company has repurchased a total of 1,910,214 shares, which represents 0.70% of its total share capital [1] - The highest price paid for the repurchased shares was 8.92 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount spent on the buyback was 16,138,029.08 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company expects a significant decline in revenue for the year 2025, projecting an operating income between 120 million to 150 million yuan, a decrease of 113.28 million to 143.28 million yuan compared to the previous year, representing a year-on-year decline of 43.03% to 54.42% [3] - The company anticipates a net loss attributable to shareholders of the parent company ranging from -160 million to -120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 55.17% to 66.38% [3] - The projected net loss attributable to shareholders after excluding non-recurring gains and losses is expected to be between -165 million to -125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 53.98% to 65.14% [4] Group 2 - The company reported a total profit loss of -388.64 million yuan for the year 2024, with a net loss attributable to shareholders of the parent company at -356.90 million yuan [6] - The earnings per share for the year 2024 were reported at -1.3007 yuan [7] Group 3 - The decline in performance is attributed to intensified market competition due to domestic pharmaceutical industry procurement policies and the introduction of similar competing products, along with a decrease in flu cases in the first three quarters of 2025, leading to reduced operating income and gross margin [8] - The company has maintained a high level of R&D investment to sustain its core competitiveness while implementing cost control measures, resulting in a significant decrease in sales and management expenses compared to the previous year [8] - Future strategies include adjusting marketing strategies, accelerating R&D progress, launching new products, optimizing product sales structure, and enhancing cost management to achieve sustainable and high-quality development [8]

Core Viewpoint - Company South New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the year 2025, primarily due to intensified market competition and reduced demand in the domestic pharmaceutical industry [1][2] Financial Performance - The projected revenue for 2025 is estimated to be between 120 million to 150 million yuan, representing a decrease of 113 million to 143 million yuan compared to the previous year, which is a year-on-year decline of 43.03% to 54.42% [1] - The expected net profit attributable to the parent company is projected to be a loss of 160 million to 120 million yuan, which is a reduction of 197 million to 237 million yuan compared to the previous year, reflecting a year-on-year decrease in losses of 55.17% to 66.38% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be a loss of 165 million to 125 million yuan, with a reduction in losses of 194 million to 234 million yuan compared to the previous year, indicating a year-on-year decrease in losses of 53.98% to 65.14% [1] Operational Factors - The decline in performance is attributed to intensified competition in the market due to domestic pharmaceutical procurement policies and the introduction of similar competing products [2] - The company has maintained a high level of R&D investment to sustain its core competitiveness despite the losses incurred [2] - Cost control measures have been implemented, resulting in a significant reduction in sales and management expenses compared to the previous year [2]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) expects a significant decline in revenue and net profit for the fiscal year 2025, indicating ongoing financial challenges for the company [1] Financial Performance Summary - The company projects an annual revenue of between 120 million to 150 million yuan for 2025, which represents a decrease of 113.2848 million to 143.2848 million yuan compared to the previous year, translating to a year-on-year decline of 43.03% to 54.42% [1] - After excluding non-core business income and income lacking commercial substance, the expected revenue is between 119.9 million to 149.9 million yuan [1] - The anticipated net profit attributable to the parent company is expected to be a loss of between 160 million to 120 million yuan, which is a reduction in loss of 196.9036 million to 236.9036 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 55.17% to 66.38% [1] - The projected net profit attributable to the parent company, after excluding non-recurring gains and losses, is expected to be a loss of between 165 million to 125 million yuan, with a reduction in loss of 193.5310 million to 233.5310 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 53.98% to 65.14% [1]

预计2025年年度归属于母公司所有者扣除非经常性损益后的净利润为-1.65亿元到-1.25亿元。与上年同 期相比，亏损减少1.94亿元到亏损减少2.34亿元，同比亏损减少53.98%到亏损减少65.14%。 本期业绩变化的主要原因：报告期内，公司生产经营活动正常。受国内医药行业集中采购等政策深入推 进、同类竞品不断上市等因素影响，导致市场竞争加剧，加之2025 年前三季度国内流感较少，导致公 司营业收入和毛利率均有所下降。报告期内，公司根据《企业会计准则》及公司会计政策等相关规定， 基于谨慎性原则，对各类资产计提资产减值损失及信用减值损失等。报告期内，为持续保持公司的核心 竞争力，公司仍保持较高强度的研发投入。基于以上因素，公司经营业绩发生亏损，但亏损幅度较上年 大幅减少。报告期内，公司持续推进各项降本增效措施，严格控制费用成本支出，全年实现销售费用、 管理费用等均较上年同期明显下降。 格隆汇1月30日丨南新制药(688189.SH)公布，经公司财务部门初步测算，预计2025年年度实现营业收入 1.2亿元到1.5亿元，与上年同期相比，将减少1.13亿元到1.43亿元，同比减少43.03%到54.42%；扣除与 ...

每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 （记者 曾健辉） 每经AI快讯，南新制药1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 将出现亏损，实现归属于母公司所有者的净利润为-1.6亿元到-1.2亿元。与上年同期相比，亏损减少约 1.97亿元到亏损减少约2.37亿元，同比亏损减少55.17%到亏损减少66.38%。业绩变动主要原因是，报告 期内，公司生产经营活动正常。受国内医药行业集中采购等政策深入推进、同类竞品不断上市等因素影 响，导致市场竞争加剧，加之2025年前三季度国内流感较少，导致公司营业收入和毛利率均有所下降。 报告期内，基于谨慎性原则，对各类资产计提资产减值损失及信用减值损失等。报告期内，为持续保持 公司的核心竞争力，公司仍保持较高强度的研发投入。基于以上因素，公司经营业绩发生亏损，但亏损 幅度较上年大幅减少。 ...

证券代码：688189 证券简称：南新制药 公告编号：2026-006 湖南南新制药股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经湖南南新制药股份有限公司（以下简称"公司"）财务部门初步测算， 预计 2025 年年度实现营业收入 12,000.00 万元到 15,000.00 万元，与上年同期 相比，将减少 11,328.48 万元到 14,328.48 万元，同比减少 43.03%到 54.42%； 扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入为 11,990.00 万元到 14,990.00 万元。 3、预计 2025 年年度归属于母公司所有者扣除非经常性损益后的净利润为 -16,500.00 万元到-12,500.00 万元。与上年同期相比，亏损减少 19,353.10 万 元到亏损减少 23,353.10 万元，同比亏 ...

南新制药公告，预计2025年年度实现归属于母公司所有者的净利润为亏损1.6亿元到-1.2亿元，与上年同 期相比，亏损减少1.97亿元到亏损减少2.37亿元，同比亏损减少55.17%到亏损减少66.38%。预计2025年 年度实现营业收入1.2亿元到1.5亿元，与上年同期相比，将减少1.13亿元到1.43亿元，同比减少43.03% 到54.42%；扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入为1.2亿元到1.5亿 元。 ...

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2026 on February 11, 2026 [1] - The meeting will be conducted both in-person and via the Shanghai Stock Exchange's online voting system [4][20] - Shareholders must register to attend the meeting, either in person or through a proxy [14][17] Group 2 - The major shareholder, Guangzhou Qianyuan Investment Consulting Partnership, held 43,120,000 shares, representing 15.71% of the total share capital before the planned reduction [24] - The reduction plan was announced on September 25, 2025, with a maximum of 8,232,000 shares to be sold, but the plan was not executed by the deadline of January 26, 2026 [25] - The major shareholder did not implement the reduction plan due to personal needs and market conditions [26] Group 3 - The company announced the resignation of independent director Shen Yunqiao due to personal reasons [27] - The board has proposed to elect Luo Zhixiong as the new independent director, who meets all legal and regulatory requirements [28][29] - Luo Zhixiong will also take on roles in various board committees upon approval at the upcoming shareholders' meeting [30]